Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 289

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 289
---
 LG Chem Acquisition of AVEO Pharmaceuticals (2023): LG Chem acquired AVEO Pharmaceuticals, a U.S. -basedoncology -focusedbiopharmaceutical company, for approximately $566 million. This acquisition aimed to enhance LG Chem’s oncology pipeline and strengthen its presence in the global biopharmaceutical market. Celltrion Acquisition of Plant in the UK from Hospira (2014): Celltrion acquired a biosimilar production facility in the UK from Hospira (now a subsidiary of Pfizer). This acquisition was part of Celltrion’s strategy to increase its manufacturing capacity and expand its presence in the European market. GC Pharma Acquisition of a Plasma Fractionation Plant from Biotest (2019): GC Pharma acquired a plasma fractionation plant in Germany from Biotest. This deal was aimed at expanding GC Pharma’s production capacity for plasma -derivedtherapies and enhancing its global supply chain. Hanmi Pharmaceutical Acquisition of Spectrum Pharmaceuticals’ Rights to Rolontis (2019): Hanmi Pharmaceutical acquired the global rights (excluding China) to Rolontis, a long -actinggranulocyte colony -stimulatingfactor, from Spectrum Pharmaceuticals. This deal, worth $160 million, included an upfront payment and milestones. Lotte Group Acquisition of Bristol -MyersSquibb’s Manufacturing Facility in Ireland (2021): Lotte Biologics, a subsidiary of Lotte Group, acquired Bristol -MyersSquibb’s biologics manufacturing facility in Swords, Ireland. The acquisition, valued at approximately $160 million, was aimed at entering the biologics CDMO business. 3)Research and Development (R&D) •Establishing R&D Centers: Large Korean companies are setting up dedicated R&D centers focusing on biotechnology and healthcare. These centers aim to drive innovation and support the development of new products and solutions. •Collaboration with Academia: Partnerships with universities and research institutions are common, fostering innovation through collaborative research projects and access to academic expertise. 172

4)Government Support and Regulation •Incentives and Funding: The Korean government provides various incentives and funding programs to support biotech and healthcare innovations, encouraging private sector investment. •Regulatory Environment: Efforts to streamline regulatory processes and provide a supportive framework for biotech development are ongoing, helping attract more investment in the sector. Fair Market Value OSR Holdings Indicative Valuation Reports In connection with diligence performed by BLAC, OSR Holdings provided certain valuation reports that were considered by BLAC